Clinical Trial Update: Apixaban to Prevent Venous Thromboembolism in Ambulatory Lung Cancer Patients Undergoing Systemic Anticancer Treatment [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating apixaban for thromboprophylaxis to prevent venous thromboembolism in ambulatory lung cancer patients undergoing systemic anticancer tre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: University of Birmingham | Conditions: Thromboprophylaxis | Phase 3 | Status: NOT_YET_RECRUITING